For a patient with atrial fibrillation, breast cancer, and hyperlipidemia who needs to hold apixaban (Eliquis) for two separate procedures, when should the drug be stopped and when can it be restarted for each procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Perioperative Management of Apixaban (Eliquis) for Two Separate Procedures

For both procedures, stop apixaban 1-2 days before low-bleeding-risk procedures and 2-3 days before high-bleeding-risk procedures; restart 24-48 hours after low-bleeding-risk procedures once hemostasis is established, and 48-72 hours after high-bleeding-risk procedures. 1

Pre-Procedure Management

Determining Bleeding Risk of Each Procedure

First, classify each procedure's bleeding risk:

Low-to-moderate bleeding risk procedures include:

  • Arthroscopy, minor skin biopsies, dental extractions, colonoscopy with biopsy, laparoscopic cholecystectomy, pacemaker implantation 2

High bleeding risk procedures include:

  • Major surgery (>45 minutes), cardiac/intracranial/spinal surgery, surgery on highly vascular organs (kidney, liver, spleen), neuraxial anesthesia, bowel resection 2

Timing of Apixaban Discontinuation

For Procedure #1:

  • Low-bleeding-risk: Stop apixaban 1-2 days before (skip 2-3 doses) 1, 2
  • High-bleeding-risk: Stop apixaban 2-3 days before (skip 4-5 doses) 1, 2

The FDA label confirms discontinuation should occur at least 24 hours before low-risk procedures and at least 48 hours before moderate-to-high-risk procedures 3.

For Procedure #2: Apply the same timing based on that procedure's bleeding risk classification.

Important Considerations

No bridging anticoagulation is needed between stopping apixaban and either procedure. The FDA label explicitly states "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 3. The rapid offset of apixaban (half-life ~12 hours) makes bridging unnecessary and potentially dangerous 1, 4.

Renal function matters less for apixaban than for dabigatran, as only 27% of apixaban clearance is renal 5. However, if this patient has significant renal impairment (CrCl <50 mL/min), consider extending the pre-procedure interruption by an additional day 6.

Post-Procedure Management

Restarting Apixaban After Each Procedure

After Procedure #1:

  • Low-bleeding-risk: Restart at 24-48 hours post-procedure once hemostasis is established 1
  • High-bleeding-risk: Restart at 48-72 hours post-procedure once hemostasis is established 1

After Procedure #2: Apply the same timing based on that procedure's bleeding risk.

The 2014 Canadian guidelines specifically recommend restarting apixaban "1 day after hemostasis is established (usually 48 hours for a procedure with low risk of bleeding and 72 hours for a procedure with an intermediate or high risk of bleeding)" 1.

Dosing Strategy Upon Restart

Resume full-dose apixaban immediately (5 mg twice daily, or 2.5 mg twice daily if patient meets dose-reduction criteria). Unlike some recommendations for dabigatran, there is no need for reduced-dose apixaban initially after high-bleeding-risk procedures 4. The Blood guidelines suggest considering reduced doses (2.5 mg twice daily) only in patients at very high thromboembolism risk, but this is optional 4.

Between the Two Procedures

Continue apixaban at the regular dose between procedures unless they are scheduled very close together. If Procedure #2 occurs before you would normally restart apixaban after Procedure #1, simply keep apixaban held and restart only after Procedure #2 according to the timing above.

Critical Pitfalls to Avoid

  1. Do NOT use heparin bridging - This significantly increases bleeding risk without reducing thromboembolism 1, 4, 3

  2. Do NOT restart apixaban too early - The 2014 Canadian guidelines emphasize that NOACs "should be restarted nearer the latter portion" of the suggested time ranges due to their rapid onset 1

  3. Do NOT assume 48 hours is always sufficient pre-procedure - Recent research shows some patients, particularly elderly with chronic kidney disease, may have detectable apixaban levels >10 days after the last dose 7

  4. Verify patient's actual renal function - If CrCl <50 mL/min, extend pre-procedure interruption times 6

  5. Confirm the patient's actual apixaban dose - Dose-reduction criteria (age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL) affect baseline anticoagulation intensity 3

Documentation for Patient

Provide written instructions specifying:

  • Date and time of last apixaban dose before each procedure
  • Date and time to restart apixaban after each procedure
  • Signs of bleeding or thromboembolism requiring immediate medical attention 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.